Stroma Liquid Biopsy For Cancer Biomarkers

Seed & Soil

  • Heterogeneous nature of cancer’s DNA
  • Characterize the stroma
  • Analyze tumor-associated microenvironment
  • Genomic and proteomic evidence
Learn more

No More Needle In The Haystack

  • Stroma and proliferating cell interaction
  • Monitor biomarker proteins
  • Highly observable measurements
Learn more

IP Supports Many New Cancer Management Strategies

  • Coagulation
  • Complement
  • Acute-phase Inflammation
Learn more

IP Supports Proteome Dysregulation In Cancer

  • Rakta Protein Panel
  • LC-MS Reporting Features
Learn more

New Cancer Targets

  • Inflammatory Response
  • Regulating factors
Learn more

IP Scope Is Vast

  • Triangle of Dysregulation
  • Personalized Medicine
Learn more

The Proteogenomic Goal

  • Characterize protease inhibitors
  • SERPIN inhibitors
Learn more

SERPIN Dysregulation in Cancer

  • Active & inactive SERPIN sub-populations
  • Partnerships and collaborations, SERPINs and cancer.
Learn more




References

1.Poster Reprint First Presented at New Jersey Cancer Retreat, May 25, 2017. Haiyan Zheng(1), Swapan Roy(2), Amenah Soherwardy(1), Seema Rahman(2), Matthew Kuruc(2); (1)Rutgers Center for Integrative Proteomics, Piscataway, NJ; (2)Biotech Support Group LLC, Monmouth Junction, NJ; entitled "Stroma Liquid Biopsy - Proteomic Profiles for Cancer Biomarkers" . Cell. 2011;144:646-674.


2.Zheng H, Zhao C, Roy S, et al. The Comparison of the Serum Proteome in Individuals with Cancers versus those without Cancer, and its application to Wellness. Poster reprint from 12th Annual US HUPO 2016 Conference, held March 13 – 16, 2016 Boston, MA, USA.


3.Zheng H, Zhao C, Roy S, et al. The Commonality of the Cancer Serum Proteome Phenotype as analyzed by LC-MS/MS, and Its Application to Monitor Dysregulated Wellness. Poster reprint from AACR Annual Meeting 2016 Conference, held April 17-20, 2016 New Orleans, LA USA

Contact Us

For Detailed Liquid Biopsy Whitepaper